ArticleJournal of immunology (Baltimore, Md. : 1950)2011
Cancer immunoediting of the NK group 2D ligand H60a.
Article in Journal of immunology (Baltimore, Md. : 1950), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.Pharmaceutical science advances · 2026Review
- Immunosurveillance encounters cancer metabolism.EMBO reports · 2024Review
- Targeting Innate Immunity in Cancer Therapy.Vaccines · 2021Review
- Arrested development: suppression of NK cell function in the tumor microenvironment.Clinical & translational immunology · 2021Article
- Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model.Nature communications · 2019Article
- NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.Frontiers in immunology · 2019Review
- Have Cells Harboring the HIV Reservoir Been Immunoedited?Frontiers in immunology · 2019Article
- Sixteen diverse laboratory mouse reference genomes define strain-specific haplotypes and novel functional loci.Nature genetics · 2018Article
- The Aryl Hydrocarbon Receptor and Tumor Immunity.Frontiers in immunology · 2018Review
- Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8Cancer immunology research · 2017Article
- Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.Nature communications · 2016Article
- NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Manipulation of Innate Immunity for Cancer Therapy in Dogs.Veterinary sciences · 2015Review
- Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.Cell reports · 2014Article
- Advantages and clinical applications of natural killer cells in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2014Review
- Article
- Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP.Journal of virology · 2013Article
- Cancer immunoediting by the innate immune system in the absence of adaptive immunity.The Journal of experimental medicine · 2012Article
- Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.Immunology and cell biology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer immunoediting describes the process whereby highly immunogenic tumor cells are removed, or edited, from the primary tumor repertoire by the immune system. In immunodeficient mice, the editing process is hampered, and "unedited" tumor cells can be recovered and studied. In this study, we compared unedited and edited tumors for their expression of NK group 2D (NKG2D) ligands, a family of surface proteins expressed on tumor cells that can activate NK cell cytotoxic activity. We found that the expression of the NKG2D ligand H60a was more heterogeneous in groups of unedited 3'-methylcholanthrene sarcoma cell lines compared with that in edited 3'-methylcholanthrene sarcoma cell lines (i.e., some unedited cell lines expressed very high levels of H60a, whereas other unedited and edited cell lines expressed very low levels). We also found that some highly immunogenic cell lines displayed a bimodal distribution consisting of H60a-hi and H60a-lo cells. In one of these cell lines, the H60a-hi cells could be removed by passaging the cells through RAG2(-/-) mice, resulting in edited cell lines that were poor targets for NK cells and that displayed progressive tumor growth. This editing of H60a-hi cells required NK cells and NKG2D. Our studies show that the expression of H60a on tumors cells can be actively modulated by the immune system, thereby implicating this NKG2D ligand in tumor immunosurveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.